A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

Don S. Dizon, Michael W. Sill, Jeanne M. Schilder, Kathryn F. McGonigle, Zia Rahman, David S. Miller, David G. Mutch, Kimberly K. Leslie

Research output: Contribution to journalArticlepeer-review

37 Scopus citations

Fingerprint Dive into the research topics of 'A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study'. Together they form a unique fingerprint.

Medicine & Life Sciences